Kevin Hahn

Title: Kevin Hahn: Innovator in Gene Therapy

Introduction

Kevin Hahn is an accomplished inventor based in Missouri City, Texas. He has made significant contributions to the field of gene therapy, particularly in the treatment of anemia and related conditions in cancer-bearing animals. With two patents to his name, Hahn's work focuses on innovative methods to enhance red blood cell counts through genetic interventions.

Latest Patents

Hahn's latest patents include groundbreaking inventions aimed at addressing anemia. The first patent, titled "Gene therapy expression of GHRH for increasing RBC count in subjects," pertains to compositions and methods useful for treating anemia and other effects commonly associated with cancer-bearing animals. This invention involves delivering an effective amount of a nucleic acid expression construct that encodes growth hormone-releasing hormone (GHRH) into the tissue of an animal, allowing for the expression of the encoded gene.

The second patent, "Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone," focuses on plasmid-mediated supplementation. This method is designed to retard tumor growth and alleviate cachexia, wasting, anemia, and other effects associated with cancer. Similar to his first patent, this invention also involves delivering a nucleic acid expression construct that encodes GHRH into specific cells, achieving tissue-specific expression.

Career Highlights

Throughout his career, Kevin Hahn has worked with notable institutions, including Baylor College of Medicine and Advisys, Inc. His research has contributed to advancements in gene therapy, particularly in the context of cancer treatment and anemia management.

Collaborations

Hahn has collaborated with esteemed colleagues such as Ruxandra Draghia-Akli and Robert Hunt Carpenter. These partnerships have furthered his research and innovation in the field of gene therapy.

Conclusion

Kevin Hahn is a prominent inventor whose work in gene therapy has the potential to transform the treatment of anemia and related conditions in cancer patients. His innovative patents reflect a commitment to advancing medical science and improving patient outcomes.